231 related articles for article (PubMed ID: 25163707)
1. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
Hughes B; Griffiths P
Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
[No Abstract] [Full Text] [Related]
2. Response to commentaries.
Wilkins C
Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
[No Abstract] [Full Text] [Related]
3. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
Rychert M; Wilkins C
Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
[TBL] [Abstract][Full Text] [Related]
4. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
Rolles S; Kushlick D
Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
[No Abstract] [Full Text] [Related]
5. Assessing the 'added value' of European policy on new psychoactive substances.
Chatwin C
Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
[TBL] [Abstract][Full Text] [Related]
6. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
Wilkins C
Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
[TBL] [Abstract][Full Text] [Related]
7. The legal regulation of narcotic drugs and psychotropic substances in the Union of Soviet Socialist Republics.
Babayan EA
Bull Narc; 1990; 42(1):73-81. PubMed ID: 2095939
[No Abstract] [Full Text] [Related]
8. Controlling new drugs under marketing regulations.
Hughes B; Winstock AR
Addiction; 2012 Nov; 107(11):1894-9. PubMed ID: 22288473
[TBL] [Abstract][Full Text] [Related]
9. New Zealand to establish fit for purpose regulation for new psychoactive substances.
Sheridan J; Atmore B; Russell B
Addiction; 2012 Nov; 107(11):1901-2. PubMed ID: 23039748
[No Abstract] [Full Text] [Related]
10. New psychoactive substances: issues about the new approach from New Zealand government.
von Diemen L
Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704
[No Abstract] [Full Text] [Related]
11. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
Rychert M; Wilkins C
Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
[TBL] [Abstract][Full Text] [Related]
12. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
Bretteville-Jensen AL
Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
[No Abstract] [Full Text] [Related]
13. Where is the pleasure?
Ritter A
Addiction; 2014 Oct; 109(10):1587-8. PubMed ID: 25163703
[No Abstract] [Full Text] [Related]
14. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
Wilkins C
Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
[TBL] [Abstract][Full Text] [Related]
15. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective.
Duffert A
Drug Test Anal; 2014; 6(7-8):876-8. PubMed ID: 24415657
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel psychoactive drugs: has it ended?
Nichols DE
J Psychoactive Drugs; 1987; 19(1):33-7. PubMed ID: 3585593
[No Abstract] [Full Text] [Related]
17. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
[TBL] [Abstract][Full Text] [Related]
18. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
Rizwan SB; Vernall AJ
BMJ; 2017 Mar; 356():j1195. PubMed ID: 28314708
[No Abstract] [Full Text] [Related]
19. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
Evans-Brown M; Sedefov R
Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
[TBL] [Abstract][Full Text] [Related]
20. Generic legislation of new psychoactive drugs.
van Amsterdam J; Nutt D; van den Brink W
J Psychopharmacol; 2013 Mar; 27(3):317-24. PubMed ID: 23343598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
